Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shamita Trivedi

Endocrinology, Diabetes & Metabolism Dallas, TX Doctor of Osteopathy

NPI 1114187903 CMS profile 1021419

12200 Park Central Dr Ste 200, Dallas, TX 75251

Open in the dashboard

General payments

$17,201

702 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shamita Trivedi of Dallas, TX is reported in the CMS Open Payments database as having received $17,201 across 702 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,522 13
2024 General $20 1
2023 General $1,780 101
2022 General $2,757 208
2021 General $2,234 141
2020 General $1,796 120
2019 General $4,092 118

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shamita Trivedi
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Shamita Trivedi were reported at $4,522. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Shamita Trivedi Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $4,092 $494 $123–$2,253 $163
2020 $1,796 $335 $85–$1,841 $114
2021 $2,234 $398 $88–$1,981 $132
2022 $2,757 $364 $88–$1,568 $149
2023 $1,780 $420 $113–$1,614 $160
2024 $20 $440 $121–$1,646 $164
2025 $4,522 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $6,095 94 payments
  2. Dexcom, Inc. $2,453 4 payments
  3. Insulet Corporation $1,749 144 payments
  4. TOLMAR Pharmaceuticals, Inc. $964 99 payments
  5. Novo Nordisk Inc $783 39 payments
  6. Alexion Pharmaceuticals, Inc. $706 47 payments
  7. Xeris Pharmaceuticals, Inc. $627 52 payments
  8. Endo Pharmaceuticals Inc. $625 46 payments
  9. Ascendis Pharma, Inc. $499 36 payments
  10. Embecta Corp. $295 15 payments
  11. Other $2,405 126 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,441 637 payments
  2. Consulting Fee $3,150 2 payments
  3. Honoraria $2,000 1 payment
  4. Travel and Lodging $1,434 6 payments
  5. Education $177 56 payments
Products named General payments · program years 2019–2025
  1. DEXCOM CGM $2,417 2 payments
  2. ARMOUR THYROID $1,092 7 payments
  3. FENSOLVI $1,026 83 payments
  4. LUPRON DEPOT $1,002 44 payments
  5. Omnipod Insulin Pump $983 81 payments
  6. Omnipod Insulin Pump $766 63 payments
  7. SUPPRELIN $564 41 payments
  8. SKYTROFA $499 36 payments
  9. GVOKE PFS $495 41 payments
  10. Strensiq $471 34 payments
  11. Other $4,377 264 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

702 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record